Pancreatic cancer remains one of the most lethal solid tumors and the 5-year survival is merely 9%. The reasons for the dismal prognosis include: the low diagnosis and resection rate at the early stage, the complex and high-risk surgical procedures and the high rate of chemoresistance and recurrence, etc.
In recent years, novel concepts and techniques have changed the diagnosis and treatment of pancreatic cancer, such as the multi-disciplinary team (MDT), liquid biopsy, neoadjuvant therapy, minimally invasive surgery and enhanced recover after surgery (ERAS). Intensive studies have been conducted to explore the diagnostic value of liquid biopsy in pancreatic cancer, and neoadjuvant therapy has improved the prognosis, especially in borderline resectable and locally advanced pancreatic cancer. In basic research, the mechanisms for pancreatic cancer progression and chemoresistance have been investigated, as well as the unique tumor microenvironment of pancreatic cancer.
However, several obstacles still remain, such as the immune therapy and targeted therapy, and translational studies are still in urgent need to improve the prognosis of pancreatic cancer.
This Research Topic aims at presenting the trends and recent advances on the clinical and translational research in the diagnosis and treatment of pancreatic cancer, as well as studies on the mechanisms of pancreatic cancer progression and chemoresistance. Novel discoveries on immune therapy and targeted therapy are also encouraged. We welcome submissions of Original Research, Mini Review and Review on the sub-topics below:
• Difficulties and countermeasures of neoadjuvant therapy for pancreatic cancer
• Application of novel chemotherapy regimens in neoadjuvant therapy of pancreatic cancer
• Effect of neoadjuvant therapy on perioperative complications of pancreatic cancer
• The advantages and limitations of minimally invasive surgery in pancreatic cancer
• The application of liquid biopsy in the early diagnosis of pancreatic cancer
• The mechanisms about the chemoresistance of pancreatic cancer and its tumour microenvironment
• Novel discoveries and progress in immune and targeted therapy of pancreatic cancer.
• The intricate relationship between diabetes, obesity and pancreatic cancer
Pancreatic cancer remains one of the most lethal solid tumors and the 5-year survival is merely 9%. The reasons for the dismal prognosis include: the low diagnosis and resection rate at the early stage, the complex and high-risk surgical procedures and the high rate of chemoresistance and recurrence, etc.
In recent years, novel concepts and techniques have changed the diagnosis and treatment of pancreatic cancer, such as the multi-disciplinary team (MDT), liquid biopsy, neoadjuvant therapy, minimally invasive surgery and enhanced recover after surgery (ERAS). Intensive studies have been conducted to explore the diagnostic value of liquid biopsy in pancreatic cancer, and neoadjuvant therapy has improved the prognosis, especially in borderline resectable and locally advanced pancreatic cancer. In basic research, the mechanisms for pancreatic cancer progression and chemoresistance have been investigated, as well as the unique tumor microenvironment of pancreatic cancer.
However, several obstacles still remain, such as the immune therapy and targeted therapy, and translational studies are still in urgent need to improve the prognosis of pancreatic cancer.
This Research Topic aims at presenting the trends and recent advances on the clinical and translational research in the diagnosis and treatment of pancreatic cancer, as well as studies on the mechanisms of pancreatic cancer progression and chemoresistance. Novel discoveries on immune therapy and targeted therapy are also encouraged. We welcome submissions of Original Research, Mini Review and Review on the sub-topics below:
• Difficulties and countermeasures of neoadjuvant therapy for pancreatic cancer
• Application of novel chemotherapy regimens in neoadjuvant therapy of pancreatic cancer
• Effect of neoadjuvant therapy on perioperative complications of pancreatic cancer
• The advantages and limitations of minimally invasive surgery in pancreatic cancer
• The application of liquid biopsy in the early diagnosis of pancreatic cancer
• The mechanisms about the chemoresistance of pancreatic cancer and its tumour microenvironment
• Novel discoveries and progress in immune and targeted therapy of pancreatic cancer.
• The intricate relationship between diabetes, obesity and pancreatic cancer
